Day: January 31, 2025

WASHINGTON — Facing intense scrutiny from U.S. senators over his potential profit from vaccine lawsuits while serving as the nation’s health secretary, Robert F. Kennedy Jr. said that if he is confirmed he will not collect fees from litigation against the drugmakers of a cervical cancer vaccine.

Kennedy, who’s President Donald Trump’s pick to lead the U.S. Health and Human Services agency, told the Senate finance committee that he would amend his ethics disclosure after several senators, including Democrat Elizabeth Warren of Massachusetts, and his cousin Caroline Kennedy raised concerns about his financial arrangement with the law firm representing patients who are claiming injuries from the vaccines.

“An amendment to my Ethics Agreement is in process, and it provides that I will divest my interest in this litigation,” Kennedy said in a written response to the committee.

Initially, Kennedy had told the committee that he would continue to accept referral fees in legal cases that don’t involve the U.S. government. That included an arrangement with a law firm that’s sued Merck over Gardasil, its human papillomavirus vaccine that prevents cervical cancer. The deal earned Kennedy $850,000 last year, and he told senators he had referred hundreds of clients to the firm.

During Wednesday’s hearing, Warren outlined several ways in which Kennedy could make it easier to sue vaccine manufacturers.

“Kennedy can kill off access to vaccines and make millions of dollars while he does it,” Warren said. “Kids might die, but Robert Kennedy can keep cashing in.”

The issue also may have been a concern for Senator Bill Cassidy, a Louisiana Republican who is also a physician and is conflicted over his vote on Kennedy’s confirmation because of Kennedy’s anti-vaccine views.

The Republican president’s nominee is “financially vested in finding fault with vaccines,” Cassidy, the chair of the health committee, noted as he ended Thursday’s confirmation hearing.

Kennedy also stopped short of making other commitments, refusing to promise that he would not engage in lobbying Health and Human Services after his term ends.

Kennedy and his supporters have railed against that sort of activity, saying the “revolving door” of Washington — where federal officials trade public service jobs to influence government agencies while in the private sector — has undermined the U.S. public health system. He has criticized the practice at least a half-dozen times in social media posts over recent years.

Kennedy, who ran for president last year before dropping his bid and endorsing Trump, vowed in one post on social media platform X to “rein in lobbyists and slam shut the revolving door,” if elected president.

He first challenged President Joe Biden for the 2024 Democratic presidential nomination but then ran as an independent before striking a deal to endorse Trump in exchange for a promise to serve in a health policy role during a second Trump administration.

Now, after two days of hearings, his shot at that job is on the line with concerns about his anti-vaccine advocacy prompting nearly all Democrats to reject his nomination and a handful of Republicans who are at least considering doing the same.

If Democrats unanimously oppose Kennedy, he’ll need support from all but three Republicans. The Senate finance committee is expected to decide if he makes it to the Senate floor for a vote next week.

Kennedy’s response to the Senate committee was first reported by The New York Times.
…

KAMPALA, UGANDA — A day after Uganda’s Ministry of Health announced a new Ebola outbreak in the capital, Kampala, most Ugandans appeared unaware or unconcerned about the outbreak and went about their business normally. But health authorities are warning Ugandans not to take Ebola lightly.

For weeks, Uganda has battled an outbreak of mpox, also known as monkeypox, that has affected more than 2,000 people and caused 13 deaths, according to the World Health Organization.

But Dr. Julius Lutwama, deputy director of the Uganda Virus Research Institute, said Ugandans need to worry more about Ebola than mpox.

“Ebola is more highly infectious even than monkeypox,” Lutwama said. “And it is even a more severe infection than monkeypox. The percentage of people that end up dead from Ebola is up to 80% while for monkeypox it is below 5%.”

Ebola killed more than 50 people in Uganda during the 2022 outbreak.

Nurse dies of Ebola

On Thursday, Dr. Diana Atwine, Uganda’s permanent secretary in the Ministry of Health, announced the new outbreak after a 32-year-old nurse died from the disease.

Atwine said the nurse sought treatment at multiple health facilities including Mulago National Referral Hospital and from a traditional healer. The patient suffered with high fever, chest pain and difficulty breathing since Jan. 20, then unexplained bleeding and multiple organ failure before dying Wednesday.

Atwine said the nurse died from the Sudan strain of Ebola.

‘We will leave it to God’

While the Ministry of Health is cautioning the public with reminders of the symptoms of Ebola, several Kampala residents who spoke to VOA said they had not heard about or were not worried about the outbreak.

Kampala resident Ntale Steven said he is not going to shut down his business.

“We will leave it to God, so the disease doesn’t spread,” he said. “And if there’s an outbreak, we should get treatment and be helped. Health workers should also care for whoever gets infected. Because we have nothing to do, we must move.”

Health authorities have moved to quarantine those who had contact with the deceased Ebola victim. Out of the 44 people in isolation, 30 are health workers from the National Referral Hospital. The rest are family members and health workers from other private facilities.

Lutwama said because it takes days before symptoms start to show, this is when most infected persons transmit the disease to others, placing health workers at a higher risk.

“Many people then can transmit it during that period, before they come to that stage of bleeding,” said Lutwama. “But still the health workers are supposed to be on the lookout. And they are also supposed to be protected, but as you know, sometimes our hospitals are missing a few things like gloves, they don’t have hypochlorite like Jik [bleach] to be able to wash their hands thoroughly and things like that.”

Even with warnings from Lutwama and the Ministry of Health, Ogwang John, a security guard, said he will take precautions only if he gets an order from his boss.

“Me, I’m not worried,” he said. “I always go with the decision of my boss. When he says that we do this, the disease is there, yes, we can take. But if he has not talked with me, I’m also a carefree man.”

The Ministry of Health said it will continue tracing contacts and monitoring those under isolation as they await more support from the World Health Organization’s contingency fund for emergencies.
…

SEOUL, SOUTH KOREA — When Chinese startup DeepSeek released its AI model this month, it was hailed as a breakthrough, a sign that China’s artificial intelligence companies could compete with their Silicon Valley counterparts using fewer resources.

The narrative was clear: DeepSeek had done more with less, finding clever workarounds to U.S. chip restrictions. However, that storyline has begun to shift.

OpenAI, the U.S.-based company behind ChatGPT, now claims DeepSeek may have improperly used its proprietary data to train its model, raising questions about whether DeepSeek’s success was truly an engineering marvel.

In statements to several media outlets this week, OpenAI said it is reviewing indications that DeepSeek may have trained its AI by mimicking responses from OpenAI’s models.

The process, known as distillation, is common among AI developers but is prohibited by OpenAI’s terms of service, which forbid using its model outputs to train competing systems.

Some U.S. officials appear to support OpenAI’s concerns. At his confirmation hearing this week, Commerce secretary nominee Howard Lutnick accused DeepSeek of misusing U.S. technology to create a “dirt cheap” AI model.

“They stole things. They broke in. They’ve taken our IP,” Lutnick said of China.

David Sacks, the White House czar for AI and cryptocurrency, was more measured, saying only that it is “possible” that DeepSeek had stolen U.S. intellectual property.

In an interview with the cable news network Fox News, Sacks added that there is “substantial evidence” that DeepSeek “distilled the knowledge out of OpenAI’s models,” adding that stronger efforts are needed to curb the rise of “copycat” AI systems.

At the center of the dispute is a key question about AI’s future: how much control should companies have over their own AI models, when those programs were themselves built using data taken from others?

AI data fight

The question is especially relevant for OpenAI, which faces its own legal challenges. The company has been sued by several media companies and authors who accuse it of illegally using copyrighted material to train its AI models.

Justin Hughes, a Loyola Law School professor specializing in intellectual property, AI, and data rights, said OpenAI’s accusations against DeepSeek are “deeply ironic,” given the company’s own legal troubles.

“OpenAI has had no problem taking everyone else’s content and claiming it’s ‘fair,'” Hughes told VOA in an email.

“If the reports are accurate that OpenAI violated other platforms’ terms of service to get the training data it has wanted, that would just add an extra layer of irony – dare we say hypocrisy – to OpenAI complaining about DeepSeek.”

DeepSeek has not responded to OpenAI’s accusations. In a technical paper released with its new chatbot, DeepSeek acknowledged that some of its models were trained alongside other open-source models – such as Qwen, developed by China’s Alibaba, and Llama, released by Meta – according to Johnny Zou, a Hong Kong-based AI investment specialist.

However, OpenAI appears to be alleging that DeepSeek improperly used its closed-source models – which cannot be freely accessed or used to train other AI systems.

“It’s quite a serious statement,” said Zou, who noted that OpenAI has not yet presented evidence of wrongdoing by DeepSeek.

Proving improper distillation may be difficult without disclosing details on how its own models were trained, Zou added.

Even if OpenAI presents concrete proof, its legal options may be limited. Although Zou noted that the company could pursue a case against DeepSeek for violating its terms of service, not all experts believe such a claim would hold up in court.

“Even assuming DeepSeek trained on OpenAI’s data, I don’t think OpenAI has much of a case,” said Mark Lemley, a professor at Stanford Law School who specializes in intellectual property and technology.

Even though AI models often have restrictive terms of service, “no model creator has actually tried to enforce these terms with monetary penalties or injunctive relief,” Lemley wrote in a recent paper with co-author Peter Henderson.

The paper argues that these restrictions may be unenforceable, since the materials they aim to protect are “largely not copyrightable.”

“There are compelling reasons for many of these provisions to be unenforceable: they chill good faith research, constrain competition, and create quasi-copyright ownership where none should exist,” the paper noted.

OpenAI’s main legal argument would likely be breach of contract, said Hughes. Even if that were the case, though, he added, “good luck enforcing that against a Chinese company without meaningful assets in the United States.”

Possible options

The financial stakes are adding urgency to the debate. U.S. tech stocks dipped Monday after following news of DeepSeek’s advances, though they later regained some ground.

Commerce nominee Lutnick suggested that further government action, including tariffs, could be used to deter China from copying advanced AI models.

But speaking the same day, U.S. President Donald Trump appeared to take a different view, surprising some industry insiders with an optimistic take on DeepSeek’s breakthrough.

The Chinese company’s low-cost model, Trump said, was “very much a positive development” for AI, because “instead of spending billions and billions, you’ll spend less, and you’ll come up with hopefully the same solution.”

If DeepSeek has succeeded in building a relatively cheap and competitive AI model, that may be bad for those with investment – or stock options – in current generative AI companies, Hughes said.

“But it might be good for the rest of us,” he added, noting that until recently it appeared that only the existing tech giants “had the resources to play in the generative AI sandbox.”

“If DeepSeek disproved that, we should hope that what can be done by a team of engineers in China can be done by a similarly resourced team of engineers in Detroit or Denver or Boston,” he said. 
…

WASHINGTON — Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin.

The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often follows surgery or injuries.

It’s the first new pharmaceutical approach to treating pain in more than 20 years, offering an alternative to both opioids and over-the-counter medications like ibuprofen and acetaminophen. But the medication’s modest effectiveness and lengthy development process underscore the challenges of finding new ways to manage pain.

Studies in more than 870 patients with acute pain because of foot and abdominal surgeries showed Vertex’s drug provided more relief than a dummy pill but didn’t outperform a common opioid-acetaminophen combination pill.

“It’s not a slam dunk on effectiveness,” said Michael Schuh of the Mayo Clinic, a pharmacist and pain medicine expert who was not involved in the research. “But it is a slam dunk in that it’s a very different pathway and mechanism of action. So, I think that shows a lot of promise.”

The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids, which are often available as generics for $1 or less.

Vertex began researching the drug in the 2000s, when overdoses were rocketing upward, principally driven by mass prescribing of opioid painkillers for common ailments like arthritis and back pain. Prescriptions have fallen sharply in the last decade and the current wave of the opioid epidemic is mainly due to illicit fentanyl, not pharmaceutical medicines.

Opioids reduce pain by binding to receptors in the brain that receive nerve signals from different parts of the body. Those chemical interactions also give rise to opioids’ addictive effects.

Vertex’s drug works differently, blocking proteins that trigger pain signals that are later sent to the brain.

“In trying to develop medicines that don’t have the addictive risks of opioid medicines, a key factor is working to block pain signaling before it gets to the brain,” Vertex’s Dr. David Altshuler, told The Associated Press last year.

Commonly reported side effects with the drug were nausea, constipation, itching, rash and headache.

“The new medication has side effect profiles that are inherently, not only different, but don’t involve the risk of substance abuse and other key side effects associated with opioids,” said Dr. Charles Argoff of the Albany Medical Center, who consulted for Vertex on the drug’s development.

The initial concept to focus on pain-signaling proteins came out of research involving people with a rare hereditary condition that causes insensitivity to pain.
…

A male nurse in Uganda has died of Ebola, the first recorded death by the disease in the East African country since an outbreak ended in 2023, health officials said.

The 32-year-old nurse worked at Mulago National Specialised Hospital in Kampala, Diana Atwine, permanent secretary of Uganda’s health ministry, said Thursday.

The nurse died Wednesday of the Sudan strain of Ebola, Atwine said.

He sought treatment at several hospitals and had also consulted with a traditional healer before tests confirmed an Ebola diagnosis, health officials said.

World Health Organization Director-General Tedros Adhanom Ghebreyesus posted on X that his organization was supporting Uganda’s efforts to contain an Ebola outbreak in Uganda with a $1 million allocation from WHO’s Contingency Fund for Emergencies.

Atwine said on her X social media account that “rapid response teams are fully deployed, contact tracing is underway, and all necessary measures are in place to contain the situation. We assure the public that we are in full control.”

Contact tracing, however, could be challenging in Kampala, with its population of 4 million people.

The health ministry, however, reported that it had identified 44 contacts of the late nurse, which included 30 other health care workers.

The symptoms of Ebola, an often fatal disease, include fever, vomiting, diarrhea, muscle pain, and at times internal and external bleeding.

According to the U.S. Centers for Disease Control and Prevention, health care workers and family members caring for someone with Ebola are at high risk for contracting the disease.

WHO said Ebola “is transmitted to people from wild animals (such as fruit bats, porcupines and non-human primates) and then spreads in the human population through direct contact with the blood, secretions, organs or other bodily fluids of infected people, and with surfaces and materials (e.g., bedding, clothing) contaminated with these fluids.”

Ebola’s fatality rate is around 50%, WHO said on its website, but it also said that fatality rates have varied from 25% to 90% in some outbreaks.
…

An estimated nine million Nigerians are deaf or have hearing impairments, and many cope with discrimination that limits their access to education and employment. But one initiative is working to change that — empowering deaf people with tech skills to improve their career prospects. Timothy Obiezu reports from Abuja.
Camera: Timothy Obiezu
…